floxuridine has been researched along with Diarrhea in 28 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 9.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer." | 9.11 | Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005) |
| "This study demonstrates that a home therapy with oral doxifluridine in elderly advanced colorectal cancer patients is feasible, with a relatively low rate of toxicity, and has moderate activity, comparable to that of intravenous 5-fluorouracil." | 9.07 | Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. ( Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 7.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 5.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer." | 5.11 | Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005) |
| "This study demonstrates that a home therapy with oral doxifluridine in elderly advanced colorectal cancer patients is feasible, with a relatively low rate of toxicity, and has moderate activity, comparable to that of intravenous 5-fluorouracil." | 5.07 | Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. ( Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 3.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "Doxifluridine is a fluoropyrimidine derivate which can be administered orally with very low toxicities." | 2.68 | Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. ( Baldini, E; Ceribelli, A; Comella, G; Conte, PF; Falcone, A; Pfanner, E; Ricci, S; Sarcina, R; Stampino, CG; Tibaldi, C, 1996) |
| "Mucositis and diarrhea are the dose-limiting toxicities when continuous infusions of FUdR and high-dose folinic acid are combined with oral hydroxyurea, effects that are consistent with the observed toxicities for FUdR when administered alone or in combination with leucovorin." | 2.67 | Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. ( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Newman, E; Raschko, JW; Somlo, G, 1994) |
| "Twenty-one stomach cancer patients and 34 colorectal cancer patients were registered in the study." | 2.67 | [Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)]. ( Hachisuka, K; Honda, H; Honda, K; Maeda, A; Nakazato, H; Tsuruga, N; Yamaguchi, A; Yoshizaki, S; Yura, J, 1994) |
| "The initial dosage was 0." | 2.67 | A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Venook, AP; Wilkinson, MJ, 1993) |
| "5'-DFUR is a promising drug for breast cancer treatment, and its tablet form makes chemotherapy easier for the patient." | 2.67 | [Co-operative clinical evaluation of 5'-DFUR tablets for breast cancer at 31 institutions]. ( Inaji, H; Miura, S; Morimoto, K; Ohta, J; Taguchi, T; Ueda, N; Yayoi, K, 1992) |
| "Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated." | 1.28 | [Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991) |
| " The optimal daily dosage was considered to be 800-1,200 mg/body/day." | 1.27 | [Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]. ( Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985) |
| "1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug." | 1.27 | [Phase II study of 5'-DFUR in gastrointestinal and breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985) |
| "Floxuridine (5-FUDR) is an antipyrimidine used in the treatment of metastatic colorectal carcinoma." | 1.27 | Radiologic manifestations of small-bowel toxicity due to floxuridine therapy. ( Gluck, WL; Gramm, HF; Kelvin, FM; Lokich, JJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (42.86) | 18.7374 |
| 1990's | 11 (39.29) | 18.2507 |
| 2000's | 4 (14.29) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C | 1 |
| Gu, Y | 1 |
| Zhao, M | 1 |
| Yuan, Y | 1 |
| Wang, F | 1 |
| Wang, Z | 1 |
| Li, W | 1 |
| Luo, H | 1 |
| Chen, C | 1 |
| Chen, G | 1 |
| Ding, P | 1 |
| Wu, X | 1 |
| Lu, Z | 1 |
| Pan, Z | 1 |
| Xu, R | 1 |
| He, Y | 1 |
| Wan, D | 1 |
| Li, Y | 1 |
| ANSFIELD, FJ | 2 |
| CURRERI, AR | 1 |
| Mishima, H | 1 |
| Kato, T | 1 |
| Yanagisawa, M | 1 |
| Tsujinaka, T | 1 |
| Nishisho, I | 1 |
| Tsujie, M | 1 |
| Fujimoto-Ouchi, K | 1 |
| Tanaka, Y | 1 |
| Kikkawa, N | 1 |
| Lee, A | 1 |
| Ezzeldin, H | 1 |
| Fourie, J | 1 |
| Diasio, R | 1 |
| Nakata, E | 1 |
| Okajima, K | 2 |
| Ishida, Y | 1 |
| Munetomo, Y | 1 |
| Gotoh, K | 1 |
| Toyohara, M | 1 |
| Miyazaki, H | 1 |
| Matsunaga, S | 1 |
| Maeura, Y | 1 |
| Fujimura, T | 1 |
| Falcone, A | 2 |
| Pfanner, E | 2 |
| Ricci, S | 2 |
| Bertuccelli, M | 1 |
| Cianci, C | 1 |
| Carrai, M | 1 |
| De Marco, S | 1 |
| Ceribelli, A | 2 |
| Barduagni, M | 1 |
| Calabresi, F | 1 |
| Raschko, JW | 1 |
| Akman, SA | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Newman, E | 1 |
| Somlo, G | 1 |
| Ahn, C | 1 |
| Doroshow, JH | 1 |
| Yamaguchi, A | 2 |
| Maeda, A | 1 |
| Hachisuka, K | 1 |
| Yura, J | 1 |
| Honda, K | 1 |
| Honda, H | 1 |
| Yoshizaki, S | 1 |
| Tsuruga, N | 1 |
| Nakazato, H | 1 |
| Levin, RD | 1 |
| Gordon, JH | 1 |
| Wilkinson, MJ | 1 |
| Frye, JW | 1 |
| Small, EJ | 2 |
| Venook, AP | 1 |
| Carroll, PR | 1 |
| Ernest, ML | 1 |
| Stagg, RJ | 1 |
| Baldini, E | 1 |
| Tibaldi, C | 1 |
| Sarcina, R | 1 |
| Comella, G | 1 |
| Stampino, CG | 1 |
| Conte, PF | 1 |
| Reese, DM | 1 |
| Corry, M | 1 |
| Seong, J | 1 |
| Cho, JH | 1 |
| Kim, NK | 1 |
| Min, JS | 1 |
| Suh, CO | 1 |
| Morimoto, K | 1 |
| Taguchi, T | 3 |
| Ohta, J | 1 |
| Miura, S | 1 |
| Ueda, N | 1 |
| Yayoi, K | 1 |
| Inaji, H | 1 |
| Kubota, Y | 1 |
| Miura, T | 1 |
| Shuin, T | 1 |
| Kinoshita, Y | 1 |
| Hosaka, M | 1 |
| Kondo, I | 1 |
| Moriyama, M | 1 |
| Fukushima, S | 1 |
| Fukuoka, H | 1 |
| Miyai, K | 1 |
| Ohmori, H | 1 |
| Matsumura, Y | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Akebi, N | 1 |
| Saika, T | 1 |
| Nanba, K | 1 |
| Tanahashi, T | 1 |
| Josen, T | 1 |
| Nasu, Y | 1 |
| Lokich, J | 2 |
| Moore, C | 2 |
| Anderson, N | 2 |
| Bern, M | 2 |
| Wallach, S | 1 |
| Williams, D | 1 |
| Terasawa, T | 2 |
| Abe, O | 2 |
| Yoshida, Y | 2 |
| Tominaga, T | 2 |
| Ogawa, N | 1 |
| Niitani, H | 1 |
| Kimura, K | 1 |
| Saito, T | 1 |
| Nakao, I | 1 |
| Urushizaki, I | 1 |
| Ohta, K | 1 |
| Kimura, T | 1 |
| Kurihara, M | 1 |
| Kitamura, M | 1 |
| Hayashi, K | 1 |
| Takahashi, I | 1 |
| Kosaki, G | 1 |
| Sakai, K | 1 |
| Irie, K | 1 |
| Yamamoto, M | 1 |
| Kawahara, T | 1 |
| Satomi, T | 1 |
| Tomita, K | 1 |
| Kelvin, FM | 1 |
| Gramm, HF | 1 |
| Gluck, WL | 1 |
| Lokich, JJ | 1 |
| Khazei, AM | 1 |
| Patel, DD | 1 |
| Morgenthaler, FR | 1 |
| MacDonald, AJ | 1 |
| Sanadizadeh, SM | 1 |
| Watkins, E | 1 |
| Moertel, CG | 1 |
| Reitemeier, RJ | 1 |
| Hahn, RG | 1 |
| Fennelly, JJ | 1 |
| Fitzgerald, MX | 1 |
| DeConti, RC | 1 |
| Kaplan, SR | 1 |
| Papac, RJ | 1 |
| Calabresi, P | 1 |
1 review available for floxuridine and Diarrhea
| Article | Year |
|---|---|
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di | 2004 |
12 trials available for floxuridine and Diarrhea
| Article | Year |
|---|---|
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas | 2014 |
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
[Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; | 1995 |
Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Diarrhea | 1994 |
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1994 |
[Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; | 1994 |
Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Female; Floxuridine; Humans; | 1993 |
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Diarrhea; Drug Administrati | 1993 |
Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Sm | 1996 |
Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2001 |
[Co-operative clinical evaluation of 5'-DFUR tablets for breast cancer at 31 institutions].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Diarrhea; Drug Administr | 1992 |
A controlled comparison of 5-fluoro-2'-deoxyuridine therapy administered by rapid intravenous injection and by continuous intravenous infusion.
Topics: Clinical Trials as Topic; Diarrhea; Drug Eruptions; Floxuridine; Humans; Hyperglycemia; Infusions, P | 1967 |
15 other studies available for floxuridine and Diarrhea
| Article | Year |
|---|---|
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2000 |
[Phase II study of 5'-DFUR (Furtulon) capsule for bladder cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Squamous | 1991 |
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru | 1991 |
Infusion of floxuridine plus etoposide plus cisplatin in human malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 1991 |
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin | 1989 |
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar | 1985 |
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
Topics: Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Administration | 1985 |
[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarr | 1985 |
[Phase II study of 5'-DFUR (5'-deoxy-5-fluorouridine) by the Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neopla | 1985 |
Radiologic manifestations of small-bowel toxicity due to floxuridine therapy.
Topics: Aged; Barium Sulfate; Diarrhea; Female; Floxuridine; Humans; Ileal Diseases; Ileum; Infusions, Intra | 1986 |
Chronic infusion of 5-fluoro-2'-deoxyuridine (5-FUDR) into the hepatic artery of the dog.
Topics: Animals; Diarrhea; Dogs; Female; Floxuridine; Gastrointestinal Hemorrhage; Hepatic Artery; Injection | 1970 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi | 1973 |